Andrew’s paper describing his development of a new antibacterial compound targeting M. tuberculosis has been published in Nature BME, titled: “Pathogen-specific antimicrobials engineered de novo through membrane-protein biomimicry.“
New Paper in Nature Biomedical Engineering!
